We encountered an abnormal hemoglobin (Rahere), with a threonine residue replacing the ,682 (EF6) lysine residue at the binding site of 2,3-diphosphoglycerate, which was responsible for overt erythrocytosis in two individuals of a Japanese family. Hemoglobin Rahere shows a lower oxygen affinity on the binding of 2,3-diphosphoglycerate or chloride ions than hemoglobin A. Although a decrease in the positive charge density at the binding sites of 2,3-diphosphoglycerate in hemoglobin Rahere apparently shifts the allosteric equilibrium toward the low affinity state, it greatly diminishes the cofactor effects by anions. The oxygen affinity of the patient's erythrocytes is substantially lowered by the presence of bezafibrate, which combines with sites different from those of 2,3-diphosphoglycerate in either hemoglobin Rahere or hemoglobin A.
Introduction
Since the discovery of the role of 2,3-diphosphoglycerate (DPG)' in regulating oxygen transport (1, 2) led to the identification of the binding sites ofanionic cofactors in the hemoglobin molecule (3, 4) , an understanding of linkage between oxygen binding and cofactor binding has been sought through studies on hemoglobin variants with alterations at the 2,3-DPG binding site (5) (6) (7) (8) (9) . Recently Perutz and Poyart (10) reported that low molecular weight compounds, such as 2-(4-chlorophenoxy)-2-methylpropionic acid (clofibric acid) and 2-[4-(2-p-chlorobenzamidethyl)-phenoxy]-2-methylpropionic acid (bezafibrate), have the remarkable ability to modify hemoglobin function in erythrocytes, a finding that opened the way to studies ofthe molecular control of hemoglobin function and its clinical application. The present paper describes the identification, in patients with erythrocytosis, of hemoglobin Rahere, in which a threonine residue substitutes for the 1382 lysine residue at the binding site of 2,3-DPG (5).
This study was undertaken to determine how this substitution affects the binding ofnatural anionic cofactors with hemoglobins, 1 . Abbreviations used in this paper: DPG, diphosphoglycerate; HPLC, high performance liquid chromatography: P50, blood oxygen tension at 50% oxygen saturation; R, high affinity; T, low affinity. and how bezafibrate interferes with alteration of the allosteric effects.
Case report. A 37-yr-old Japanese man was admitted to Kyushu University Hospital, Fukuoka City, Japan for evaluation of glycosuria and erythrocytosis. 20 yr previously, he was noted to have erythrocytosis, but had no further examinations performed at the time. The patient appeared to be plethoric, without other physical abnormalities. Hemoglobin was 20.5 g/dl; erythrocytes, 5.88 million/mm3; hematocrit, 61%; mean corpuscular hemoglobin, 34.8 pg; mean corpuscular hemoglobin concentration, 33.6%; mean corpuscular volume, 103.7 ,um3; reticulocytes, 0.5%; leukocytes, 6,600/mm3; and platelets, 12.3 X 104/mm3. Sternal marrow examination showed normoblastic hyperplasia, with a myeloid-to-erythroid ratio of 0.90 to 1. The total erythrocyte mass was 47.7 ml/kg ofbody weight, exceeding the normal limit of 36.0 ml/kg of body weight. Oxygen and carbon dioxide tensions in the arterial blood were 87.1 mmHg and 38.3 mmHg, and in the venous blood were 47.7 mmHg and 42.6 mmHg, respectively. Blood glucose levels were 120 mg/dl at fast, and 147 mg/dl 120 min after ingestion of 75 g glucose. The glycosylated hemoglobin fraction (Alc) was determined to be 51.8% of the total hemoglobin. The unusually high hemoglobin Alc concentration prompted us to search for an abnormal hemoglobin as a possible cause of erythrocytosis in this individual.
Family study discovered that an apparently healthy, 1 8-yrold son of the patient had the erythrocytosis and hemoglobin variant seen in the father. Hematological data were: hemoglobin, 18.4 g/dl; erythrocytes, 5.71 million/mm3; hematocrit, 51%; and leukocytes, 6,300/mm3.
Methods
Packed erythrocytes were washed with 0.9% NaCl and subsequently lysed in water and CCL4. The methods for electrophoresis ofhemoglobins either on a thin-layer starch gel plate ( 11) or on a cellulose acetate sheet (12) , determination ofrelative concentration ofhemoglobins by ion-exchange high performance liquid chromatography (HPLC) (13) , purification of hemoglobins by chromatography on a DEAE-cellulose column (14) , preparation of globins, and separation and aminoethylation of a-chains and 3-chains (15) Diagnostics) on the oxygen equilibria of erythrocytes and hemoglobin solutions were studied as described elsewhere (10) . Hemoglobin concentrations were determined spectrophotometrically, using the extinction coefficients of hemoglobin A (9) . Methemoglobin concentrations in solutions of hemoglobin isolated by chromatography remained <1%, as determined before equilibria measurements by the method described previously (9) .
Results
Electrophoresis of hemolysates detected a hemoglobin variant, subsequently identified as hemoglobin Rahere (5) , that migrated anodally to hemoglobin A at pH 8.6 . Electrophoretic mobility of the variant on a cellulose acetate sheet was +3.07 at pH 8.6, measured by the method of Schneider and Barwick (12) . Hemoglobins A2, A, Rahere (or A,), and the glycosylated derivative ofhemoglobin Rahere composed 2.83%, 44.9%, 47.7%, and 4.5% ofthe total hemoglobins, respectively. Concentration of2,3-DPG was 3.48 gmol/ml erythrocytes in the patient (mean ofduplicate determinations), being slightly below the normal range of 4.34±0.58 (SD) ,mol/ml erythrocytes.
Amino acid substitution. Separation of trypsin peptides of the aminoethylated (3-chains from the variant is shown in Fig.   1 . It was apparent that normal #T9 and ,BT10 peptides were absent in the peptide chromatograms, while three new peptides, (3T8/9/10, (3T9/10, and (3T9/I0/1 1, were found, each corre- from these results that the substitution must be a threonine residue for a lysine residue at position 82 of the 13-chains. This variant, therefore, is identical with hemoglobin Rahere that has been found in an English family by Lorkin et al. (5) . Oxygen equilibria. Fig. 2 shows that stripped hemoglobin Rahere has lower oxygen affinities than do solutions of hemoglobin A in 0.05 M Hepes buffer at pH 7.4. In addition, the variant is much less affected by 2,3-DPG cofactor. The Bohr effects are compared in Table II , showing that the slopes of the curves, as expressed by -A log P50/ApH (where P50 is the blood oxygen tension at 50% oxygen saturation), for both hemoglobins A and Rahere are similar. Nevertheless, there may be a small Bohr effect difference between the two hemoglobins. As shown in Fig. 3 , the Bohr effect of hemoglobin Rahere is greatly reduced relative to that ofhemoglobin A when compared in the presence of 2,3-DPG. A distinctive feature ofthe substitutions ofa neutral , , The n values at half(50%) saturation point (nl/2) are typically 2.8 to 3.0 from pH 6 to pH 9. Fig. 4 shows the effects of 2,3-DPG and bezafibrate on purified hemoglobin Rahere and hemoglobin A in the presence of0.1 M NaCl at pH 7.4 and 370C. Bezafibrate lowers the oxygen affinity of hemoglobin Rahere as strongly as that of hemoglobin A. This contrasts with the finding that 2,3-DPG has no effects on the oxygen dissociation curves of hemoglobin Rahere under the same conditions.
Oxygen dissociation curves of the patient's erythrocytes at 370C are compared with a normal curve in Fig. 5 . The blood oxygen tension at 50% oxygen saturation (P50) is 22 mmHg compared with the normal value of 31 mmHg. 30 min after incubation with 5 mM bezafibrate in Hepes buffer at pH 7.2 and 370C, the P50 value for patient's erythrocytes containing both hemoglobin Rahere and hemoglobin A increased from 31.6 to 44.6 mmHg, and that for normal erythrocytes increased from 39.8 to 58.6 mmHg, respectively. Thus, in the absence or presence of 5 mM bezafibrate, the log P50 values for normal erythrocytes differ by +0.17, and the values for patient's erythrocytes differ by +0.15, an equal degree of curve shifts being observed.
Discussion
The 382 (EF6) lysine residues in human hemoglobin are involved in the binding of anionic cofactors (3, 4) . When a cofactor binds to this site the allosteric equilibrium between the high affinity (R) and low affinity (T) conformations is shifted toward the T state (3) . This residue is replaced by a threonine residue in hemoglobin Rahere (5), by methionine in hemoglobin Helsinki (8), and by asparagine in hemoglobin Providence (9) . bine with different binding sites in the hemoglobin molecule. It is relevant to this discussion that formation of the T state is opposed by the positive charges of (82 lysine residues and the other members of the charge cluster that form the 2,3-DPG binding site (9) . Also, a pair of charged side chains that form the bezafibrate binding site (10) may contribute to this effect, since it suggests a basis for the additional decrease in oxygen affinity, which is observed when both cofactors are bound to the hemoglobin molecule. Bezafibrate also enhances the Bohr effect for hemoglobin Rahere. X-ray crystallographic analyses have shown that bezafibrate binds to a pair of sites between the two a-chains in the central cavity of the hemoglobin A molecule (10) . In view of this evidence, bezafibrate may be thought to combine with the site formed between the amino and carboxyl termini of opposite a-chains of deoxyhemoglobin. Perutz and TenEyck (22) and Fermi (23) reported that there were four salt bridges, all involving terminal residues, in deoxyhemoglobin that were broken upon oxygenation. The presence of three of these has been confirmed by x-ray crystallography at high resolution (23) . Also, the first two residues of the amino terminus of the a-chains might, under physiologic conditions, form salt bridges between opposing a-chain termini, but these are broken at high salt concentration (23) . These salt bridges between the NH2 terminal and COOH-terminal residues of the a-chains facing the central cavity in deoxyhemoglobin might be stabilized by the bezafibrate molecule held in place by polar interactions with these groups. The results in this paper support the previous observation that bezafibrate and 2,3-DPG enhance each other's effect additively on oxygen dissociation curves for normal hemoglobin (10) . While the natural allosteric effector influences only hemoglobin A, but not hemoglobin Rahere in erythrocytes, bezafibrate combines with both hemoglobins, thereby shifting the oxygen equilibrium curves for those hemoglobins toward the low affinity forms. The erythrocyte membrane is permeable to bezafibrate. Although the results described herein are encouraging from a clinical viewpoint, it remains to be seen whether a bezafibrate dose (450 mg-600 mg/d) as used in the therapy of hyperlipidemia patients (24) can build a concentration of this drug in erythrocytes sufficient to benefit the oxygen transport capacity. It is important to realize that the oral dose ofbezafibrate employed in the therapy of hyperlipidemia patients will yield a plasma concentration at least an order of magnitude below that employed in the in vitro work presented in this paper. I Q-I a-
